amylase

Amylase (Diastase) is any one of a group of enzymes which catalyses the breakdown of starch into maltose.

α-Amylase-IN-1 is an α-Amylase inhibitor (IC50: 0.5509 μM). α-Amylase-IN-1 has antioxidant activity with an IC50 value of 53.49 μM for scavenging of DPPH free radicals, and can be used in the study of diabetes and oxidative stress-related diseases.

Hemipyocyanine (528-71-2) is the virulence factor of Gram-negative, aerobic rod bacterium Pseudomonas aeruginosa. Hemipyocyanine is an α-Amylase inhibitor.

Trilobatin (P-Phlorizin) has anti-oxidant effect, can increase superoxide dismutase (SOD) activity.Trilobatin has anti-inflammatory effect, it potentially inhibits the lipopolysaccharide (LPS)-induced inflammatory response by suppressing the NF-κB signaling pathway.Trilobatin shows a strong inhibitory activity against α-glucosidase and a moderate inhibitory activity against α-amylase for management of postprandial hyperglycemia with less side effect.

7,4'-Di-O-methylapigenin (4',7-DIMETHOXY-5-HYDROXYFLAVONE) can inhibit α-glucosidase and α-amylase enzymes and enhance 2-NBDG uptake in L6 cells, it has hypolipidemic effect on mouse pre-adipocyte (3T3L1) cell lines.

Isookanin shows strong diphenyl(2,4,6-trinitrophenyl)iminoazanium (DPPH) radical-scavenging activity with the IC50 value of 7.9 ± 0.53 μM. Isookanin is a potent inhibitor of α-amylase (IC50=0.447 mg/ml).

Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside) is a flavonol from Morettia philaena that inhibits α-amylase, α-glucosidase, and acetylcholinesterase. It exhibits neuroprotective activity, slowing amyloid β peptide-induced damage in differentiated neuronal cells SH-SY5Y, and can be used in the study of neurological disorders such as Alzheimer's disease.

α-Amylase-IN-7 (Compound 6e) is an inhibitor of α-Amylase, with an IC50 of 40 μM, indicating its potency. This compound shows potential as an anti-diabetic medication.

α-Amylase-IN-3 is a multi-target inhibitor of α-amylase (IC50=18.04 μM) and cholinesterases (AChE/BChE). It exhibits antioxidant activity for diabetes and neurodegeneration research.

α-Amylase/α-Glucosidase-IN-5 (compound 4l) functions as a dual inhibitor, effectively inhibiting both α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50 values of 5.96 μM and 1.62 μM, respectively, exhibiting potential for antidiabetic activity [1].

α-Amylase/α-Glucosidase-IN-3 (Compound 17) is a dual inhibitor of α-Amylase and α-Glucosidase, with IC50 values of 0.70 μM and 1.10 μM, respectively, applicable for type-II diabetes mellitus research [1].

α-Amylase/α-Glucosidase-IN-4 (compound 5), a dual inhibitor targeting α-amylase (Amylases) and α-glucosidase (Glucosidase), exhibits potent inhibition with IC50 values of 1.10 μM and 0.15 μM respectively, and is noted for its potential antidiabetic activity [1].

α-Amylase-IN-4 (Compd 10y) exhibits the highest amylase inhibition with an IC50 value of 17.83 ± 0.14 μg/mL [1].

α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50 values of 17.0 µM and 40.1 µM, respectively, and demonstrates anti-hyperglycemic activities [1].

α-Amylase, Human Pancreas (Amylase, a-Amylase, 1,4-a-D-glucan glucanohydrolase, glycogenase) serves as a biological material or organic compound suitable for life sciences research.

Quercimeritrin (Quercetin-7-O-beta-D-glucopyranoside) has antibacterial activity, it shows promising activity against Staphylococcus aureus.

α-Amylase-IN-9 (Compound 1i) is an inhibitor of α-Amylase with an IC50 value of 14.64 μM and is utilized in diabetes research.

α-Amylase-IN-10 (Compound 15n) is an inhibitor of α-Amylase, with an IC50 of 5.00 µM. This compound is applicable for research in type 2 diabetes.

α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 49.17 nM and 10.71 nM, respectively. It is suitable for research related to type 2 diabetes.

α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 14.61 μM and 25.38 μM, respectively. It exhibits some inhibitory activity against A549 cancer cells and possesses both antitumor and antidiabetic properties.

α-Amylase-IN-11 (compound C5f) is an α-amylase inhibitor with an IC50 of 0.56 μM, effective in reducing glucose levels in vivo. Additionally, it exhibits moderate inhibitory activity against α-glucosidase with an IC50 of 11.03 μM. In mouse models, α-Amylase-IN-11 significantly decreases glucose concentrations, indicating its potential for diabetes research.

α-Amylase-IN-12 (Compound 5e) is an α-amylase inhibitor with an IC50 of 0.15 mM, functioning through a mixed inhibition mode. It exhibits an IC50 of 9.40 mM against α-glucosidase. This compound enhances glucose uptake in yeast cells and demonstrates significant anti-glycation activity at high concentrations. α-Amylase-IN-12 is applicable for diabetes research.

α-Amylase/α-Glucosidase-IN-19 (compound 10) is a dual inhibitor of α-amylase and α-glucosidase, with an IC50 of 170.7 μM and 60.37 μM, respectively.

α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50 values of 10.19 μM and 10.33 μM, respectively. It also exhibits significant antioxidant activity (IC50= 14.93 μM). This compound is applicable in diabetes research.